[A18-23] Bezlotoxumab (Clostridium difficile infection) - Benefit assessment according to §35a Social Code Book V
Last updated 02.07.2018
Commission awarded on 29.03.2018 by the Federal Joint Committee (G-BA).
Immune system and infections
Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI
Proof of non-quantifiable (at most considerable) added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.